Product Description
Chong Kun Dang was developing ckd-337, an oral HMG-CoA Inhibitor,PPAR-a Activator, for the treatment of Dyslipidemias (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03346187)
Mechanisms of Action: HMG-CoA Inhibitor,PPAR-a Activator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Chong Kun Dang
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Dyslipidemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
146FDI17001 | P1 |
Completed |
Dyslipidemia |
2017-11-02 |
|
146BE16007 | P1 |
Completed |
Dyslipidemia |
2017-05-31 |
|
146BE15025 | P1 |
Completed |
Dyslipidemia |
2016-03-01 |